The University of California Lung Cancer Consortium and AstraZeneca announced a five-year partnership to expand the Healthy Lungs California initiative, which is aimed at increasing early lung cancer detection and reducing deaths from the disease.
Most patients who enroll in the Lung-MAP precision medicine trial in non-small cell lung cancer can now be matched to a targeted investigational treatment based on the results of their prior genomic testing, without needing to submit new tumor or blood samples.
